How to buy Syndax Pharmaceuticals stock

Syndax Pharmaceuticals, Inc is a biotechnology business based in the US. Syndax Pharmaceuticals shares (SNDX) are listed on the NASDAQ and all prices are listed in US Dollars. Syndax Pharmaceuticals employs 43 staff and has a trailing 12-month revenue of around 0.00.

Syndax Pharmaceuticals share price

Use our graph to track the performance of SNDX stocks over time.

Syndax Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$11.27 - $27.12
50-day moving average	$22.08
200-day moving average	$21.61
Wall St. target price	$29.60
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.36

Buy Syndax Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Syndax Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Syndax Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Syndax Pharmaceuticals financials

Revenue TTM	$1.5 million
Gross profit TTM	$1.5 million
Return on assets TTM	-24.52%
Return on equity TTM	-51.56%
Profit margin	0%
Book value	$5.27
Market capitalisation	$757.7 million

TTM: trailing 12 months

Shorting Syndax Pharmaceuticals shares

There are currently 6.8 million Syndax Pharmaceuticals shares held short by investors – that's known as Syndax Pharmaceuticals's "short interest". This figure is 28% up from 5.3 million last month.

There are a few different ways that this level of interest in shorting Syndax Pharmaceuticals shares can be evaluated.

Syndax Pharmaceuticals's "short interest ratio" (SIR)

Syndax Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Syndax Pharmaceuticals shares currently shorted divided by the average quantity of Syndax Pharmaceuticals shares traded daily (recently around 876738.19354839). Syndax Pharmaceuticals's SIR currently stands at 7.75. In other words for every 100,000 Syndax Pharmaceuticals shares traded daily on the market, roughly 7750 shares are currently held short.

However Syndax Pharmaceuticals's short interest can also be evaluated against the total number of Syndax Pharmaceuticals shares, or, against the total number of tradable Syndax Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Syndax Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Syndax Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0.1435% of the tradable shares (for every 100,000 tradable Syndax Pharmaceuticals shares, roughly 144 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Syndax Pharmaceuticals.

Find out more about how you can short Syndax Pharmaceuticals stock.

Syndax Pharmaceuticals share dividends

We're not expecting Syndax Pharmaceuticals to pay a dividend over the next 12 months.

Syndax Pharmaceuticals share price volatility

Over the last 12 months, Syndax Pharmaceuticals's shares have ranged in value from as little as $11.27 up to $27.1189. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syndax Pharmaceuticals's is 1.7871. This would suggest that Syndax Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Syndax Pharmaceuticals overview

Syndax Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co. , Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

• What percentage of Syndax Pharmaceuticals is owned by insiders or institutions?

  Currently 4.745% of Syndax Pharmaceuticals shares are held by insiders and 103.754% by institutions.

• How many people work for Syndax Pharmaceuticals?

  Latest data suggests 43 work at Syndax Pharmaceuticals.

• When does the fiscal year end for Syndax Pharmaceuticals?

  Syndax Pharmaceuticals's fiscal year ends in December.

• Where is Syndax Pharmaceuticals based?

  Syndax Pharmaceuticals's address is: 35 Gatehouse Drive, Waltham, MA, United States, 02451

• What is Syndax Pharmaceuticals's ISIN number?

  Syndax Pharmaceuticals's international securities identification number is: US87164F1057

• What is Syndax Pharmaceuticals's CUSIP number?

  Syndax Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 87164F105